Topical PDE-4 Inhibitors are Emerging for Psoriasis Treatment

Abstract

Keywords

psoriasis roflumilast PDE-4 inhibitors topical treatment

Get full access to this article

View all access options for this article.

References

Canadian Psoriasis Guidelines Addendum Committee . 2016 addendum to the Canadian guidelines for the management of plaque psoriasis 2009. J Cutan Med Surg. 2016;20(5):375-431.doi:10.1177/1203475416655705

27421294

Moustafa

Feldman

. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20(5):22608.

24852768

Snape

SD.

Wigger-Alberti

Goehring

. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test. Br J Dermatol. 2016;175(3):479-486.doi:10.1111/bjd.14634

27038440

Lebwohl

MG.

Papp

KA.

Stein Gold

et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229-239.doi:10.1056/NEJMoa2000073

32668113

Hashim

PW.

Chima

Kim

et al. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double-blind, randomized, vehicle-controlled trial. J Am Acad Dermatol. 2020;82(2):360-365.doi:10.1016/j.jaad.2019.06.1288

31279028